China National Accord Medicines (SZSE:200028) Debt-to-Equity

: 0.29 (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

China National Accord Medicines's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$3,973 Mil. China National Accord Medicines's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,588 Mil. China National Accord Medicines's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$19,048 Mil. China National Accord Medicines's debt to equity for the quarter that ended in Dec. 2023 was 0.29.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for China National Accord Medicines's Debt-to-Equity or its related term are showing as below:

SZSE:200028' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.17 Med: 0.24 Max: 0.33
Current: 0.29

During the past 13 years, the highest Debt-to-Equity Ratio of China National Accord Medicines was 0.33. The lowest was 0.17. And the median was 0.24.

SZSE:200028's Debt-to-Equity is ranked better than
50.6% of 83 companies
in the Medical Distribution industry
Industry Median: 0.29 vs SZSE:200028: 0.29

China National Accord Medicines Debt-to-Equity Historical Data

The historical data trend for China National Accord Medicines's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China National Accord Medicines Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.25

0.27

0.28

0.22

0.29

China National Accord Medicines Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.22	0.35	0.38	0.40	0.29

Competitive Comparison

For the Medical Distribution subindustry, China National Accord Medicines's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China National Accord Medicines Debt-to-Equity Distribution

For the Medical Distribution industry and Healthcare sector, China National Accord Medicines's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where China National Accord Medicines's Debt-to-Equity falls into.

China National Accord Medicines Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

China National Accord Medicines's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3972.61	+	1587.935)	/	19047.95
	=	0.29

China National Accord Medicines's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3972.61	+	1587.935)	/	19047.95
	=	0.29

China National Accord Medicines (SZSE:200028) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

China National Accord Medicines Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of China National Accord Medicines's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

China National Accord Medicines (SZSE:200028) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Accord Medicines Corp Ltd (SZSE:200028) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

000028:China

Address

No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029

Website

http://www.szaccord.com.cn

China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.

China National Accord Medicines (SZSE:200028) Headlines

No Headlines